ChiCTR2100048734: Safety and Effectiveness of Lonasen Post-marketing Surveillance in Treatment of Chinese Schizophrenia Patients |
|
|
| Recruiting | 4 | 3000 | | Nil | The Second Xiangya Hospital of Central South University; Sumitomo Pharmaceutical (Suzhou) Co., Ltd., Sumitomo Pharmaceutical (Suzhou) Co., Ltd. | Schizophrenia | | | | |
NCT03784222: Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients |
|
|
| Terminated | 4 | 102 | RoW | Blonanserin, MRI and serum BDNF | Sumitomo Pharma (Suzhou) Co., Ltd. | First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin | 11/22 | 11/22 | | |
| Completed | 1 | 72 | | In the fasting state, oral dose of 4mg, then 8mg, and finally 12mg ;In the fasting state, oral dose of 8mg, then 12mg, and finally 4mg ;In the fasting state, oral dose of 12mg, then 4mg, and finally 8mg ;Given 4mg twice a day, till 9 times ;Single oral dose of 4mg in the fasting state, then single oral dose of 4mg in the fed state ;Single oral dose of 4mg in the fed state, then single oral dose of 4mg in the fasting state | The first affiliated hospital, School of Medicine, Zhejiang University; Jiangsu Hansoh Pharmaceutical Company, Provided by Jiangsu Hansoh Pharmaceutical Company | schizophrenia | | | | |
ChiCTR2200055572: Efficacy and Safety of Switching to or Combination with Blonanserin for Treatment-resistant Schizophrenia: a Medical Records Based Retrospective Cohort Study |
|
|
| Recruiting | N/A | 100 | | Nil | Huzhou Third People's Hospital; Huzhou Third People's Hospital, self-funding | treatment-resistant schizophrenia | | | | |
